Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemo + Bevacizumab in Advanced Cervical Cancer
NCT04973904Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Cervical Cancer (CC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall Response Rate at 1 year. Status: unknown.
02
Drugs
toripalimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04973904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973904.